Literature DB >> 23615681

Delay in surgical treatment and survival after breast cancer diagnosis in young women by race/ethnicity.

Erlyn C Smith1, Argyrios Ziogas, Hoda Anton-Culver.   

Abstract

IMPORTANCE: Breast cancer in women between the ages of 15 and 39 years (adolescents and young adults [AYAs]) constitutes 5% to 6% of all breast cancer cases in the United States. Breast cancer in AYA women has a worse prognosis than in older women. Five-year survival rates are lowest for AYA women, and only a few studies have examined the impact of delay in treatment, race/ethnicity, and other socioeconomic factors on survival in AYA women.
OBJECTIVE: To examine the impact of treatment delay time (TDT), race/ethnicity, socioeconomic status, insurance status, cancer stage, and age on the survival from breast cancer among AYA women. DESIGN, SETTING, AND PARTICIPANTS: This is a retrospective case-only study of 8860 AYA breast cancer cases diagnosed from 1997 to 2006 using the California Cancer Registry database. EXPOSURE: Treatment delay time was defined as the number of weeks between the date of diagnosis and date of definitive treatment. Kaplan-Meier estimation was used to generate survival curves, and a multivariate Cox proportional hazards regression model was performed to assess the association of TDT with survival while accounting for covariates (age, race/ethnicity, socioeconomic status, insurance status, cancer stage [American Joint Committee on Cancer], tumor markers, and treatment). MAIN OUTCOMES AND MEASURES: Five-year survival rates for breast cancer as influenced by host factors, tumor factors, and TDT.
RESULTS: Treatment delay time more than 6 weeks after diagnosis was significantly different (P < .001) between racial/ethnic groups (Hispanic, 15.3% and African American, 15.3% compared with non-Hispanic white, 8.1%). Women with public or no insurance (17.8%) compared with those with private insurance (9.5%) and women with low socioeconomic status (17.5%) compared with those with high socioeconomic status (7.7%) were shown to have TDT more than 6 weeks. The 5-year survival in women who were treated by surgery and had TDT more than 6 weeks was 80% compared with 90% (P = .005) in those with TDT less than 2 weeks. In multivariate analysis, longer TDT, estrogen receptor negative status, having public or no insurance, and late cancer stage were significant risk factors for shorter survival.
CONCLUSIONS: AND RELEVANCE: Young women with breast cancer with a longer TDT have significantly decreased survival time compared with those with a shorter TDT. This adverse impact on survival was more pronounced in African American women, those with public or no insurance, and those with low SES.

Entities:  

Mesh:

Year:  2013        PMID: 23615681     DOI: 10.1001/jamasurg.2013.1680

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  75 in total

1.  Racial Differences in Time to Breast Cancer Surgery and Overall Survival in the US Military Health System.

Authors:  Yvonne L Eaglehouse; Matthew W Georg; Craig D Shriver; Kangmin Zhu
Journal:  JAMA Surg       Date:  2019-03-20       Impact factor: 14.766

2.  Race and breast cancer survival by intrinsic subtype based on PAM50 gene expression.

Authors:  Candyce H Kroenke; Carol Sweeney; Marilyn L Kwan; Charles P Quesenberry; Erin K Weltzien; Laurel A Habel; Adrienne Castillo; Phillip S Bernard; Rachel E Factor; Lawrence H Kushi; Bette J Caan
Journal:  Breast Cancer Res Treat       Date:  2014-03-07       Impact factor: 4.872

3.  Racial/ethnicity disparities in invasive breast cancer among younger and older women: An analysis using multiple measures of population health.

Authors:  Mei-Chuan Hung; Donatus U Ekwueme; Sun Hee Rim; Arica White
Journal:  Cancer Epidemiol       Date:  2016-10-25       Impact factor: 2.984

4.  Time to Surgery: a Misguided Quality Metric in Early Stage Pancreatic Cancer.

Authors:  Katelin A Mirkin; Christopher S Hollenbeak; Joyce Wong
Journal:  J Gastrointest Surg       Date:  2018-03-08       Impact factor: 3.452

5.  Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence.

Authors:  Tanya Keenan; Beverly Moy; Edmund A Mroz; Kenneth Ross; Andrzej Niemierko; James W Rocco; Steven Isakoff; Leif W Ellisen; Aditya Bardia
Journal:  J Clin Oncol       Date:  2015-09-14       Impact factor: 44.544

6.  Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome.

Authors:  Adam C Yopp; John C Mansour; Muhammad S Beg; Juan Arenas; Clayton Trimmer; Mark Reddick; Ivan Pedrosa; Gaurav Khatri; Takeshi Yakoo; Jeffrey J Meyer; Jacqueline Shaw; Jorge A Marrero; Amit G Singal
Journal:  Ann Surg Oncol       Date:  2013-12-07       Impact factor: 5.344

7.  Quality Of Breast Cancer Care In The US Territories: Insights From Medicare.

Authors:  Tracy M Layne; Jenerius A Aminawung; Pamela R Soulos; Marcella Nunez-Smith; Maxine A Nunez; Beth A Jones; Karen H Wang; Cary P Gross
Journal:  Health Aff (Millwood)       Date:  2018-03       Impact factor: 6.301

8.  Race and delays in breast cancer treatment across the care continuum in the Carolina Breast Cancer Study.

Authors:  Katherine E Reeder-Hayes; Sophie E Mayer; Andrew F Olshan; Stephanie B Wheeler; Lisa A Carey; Chiu-Kit Tse; Mary Elizabeth Bell; Melissa A Troester
Journal:  Cancer       Date:  2019-08-09       Impact factor: 6.860

9.  Breast cancer treatment delays by socioeconomic and health care access latent classes in Black and White women.

Authors:  Marc A Emerson; Yvonne M Golightly; Allison E Aiello; Katherine E Reeder-Hayes; Xianming Tan; Ugwuji Maduekwe; Marian Johnson-Thompson; Andrew F Olshan; Melissa A Troester
Journal:  Cancer       Date:  2020-09-21       Impact factor: 6.860

10.  Treatment Costs of Breast Cancer Among Younger Women Aged 19-44 Years Enrolled in Medicaid.

Authors:  Donatus U Ekwueme; Benjamin T Allaire; Gery P Guy; Sarah Arnold; Justin G Trogdon
Journal:  Am J Prev Med       Date:  2016-02       Impact factor: 5.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.